What is Brian Allen Carrico’s reported NRXS share position after this RSU grant?

After the award, Brian Allen Carrico’s directly held position reported in the Form 4 is 193,329 shares of common stock underlying RSUs, reflecting the full amount of this new equity grant.

Neuraxis (NRXS) hands CEO 193K stock units vesting over 3 years

Q: What equity award did NRXS grant to CEO Brian Allen Carrico?

Brian Allen Carrico received a grant of 193,329 restricted stock units (RSUs) as compensation under Neuraxis, Inc. 2022 Omnibus Securities and Incentive Plan, as amended, according to this Form 4.

Q: How do the NRXS RSUs granted to Brian Allen Carrico vest?

The 193,329 RSUs granted to Brian Allen Carrico vest in three equal annual installments over a three-year period , meaning one-third of the units become vested each year during that timeframe.

Q: Was the NRXS CEO’s RSU transaction under a Rule 10b5-1 trading plan?

No. The filing’s Rule 10b5-1 checkbox is not marked as affirmative , indicating this RSU compensation grant was not reported as being made pursuant to a Rule 10b5-1 trading plan.

Q: What is the transaction price field for the NRXS RSU grant to the CEO?

The Form 4 reports a transaction price per unit of $6.2800 for the 193,329 RSUs . This figure is disclosed in the transaction data field associated with the equity award.

Filing Impact

(Very High)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

Carrico Brian Allen reported acquisition or exercise transactions in this Form 4 filing.

Neuraxis, Inc. (NRXS) reported that Chief Executive Officer and director Brian Allen Carrico received a grant of 193,329 restricted stock units (RSUs) as equity compensation under the Neuraxis, Inc. 2022 Omnibus Securities and Incentive Plan, as amended. The RSUs vest in three equal annual installments over a three-year period. Following this award, his directly held RSU-based common stock position reported in this filing is 193,329 shares.

Insights

Analyzing...

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Carrico Brian Allen

Role Chief Executive Officer

Type	Security	Shares	Price	Value
Grant/Award	RSU ^F1	193,329	$6.28	$1.21M

Holdings After Transaction: RSU — 193,329 shares (Direct)

Footnotes (1)

F1. These shares of common stock are restricted stock units (RSUs) granted to the reporting person as compensation under Neuraxis, Inc. 2022 Omnibus Securities and Incentive Plan, as amended. The RSUs vest in three equal annual installments over a three-year period.

Key Figures

RSUs granted: 193,329 shares Transaction price field: $6.2800 per share Shares following transaction: 193,329 shares +2 more

5 metrics

RSUs granted 193,329 shares Restricted stock units granted as compensation to the CEO

Transaction price field $6.2800 per share Price per unit reported for the RSU grant

Shares following transaction 193,329 shares Directly held position reported after the RSU award

Vesting period 3 years RSUs vest in three equal annual installments over three years

Number of vesting installments 3 installments RSUs vest in three equal annual installments

Key Terms

restricted stock units (RSUs), 2022 Omnibus Securities and Incentive Plan, vesting

3 terms

restricted stock units (RSUs) financial

"These shares of common stock are restricted stock units (RSUs) granted"

Restricted stock units (RSUs) are a type of company promise to give employees shares of stock in the future, usually after certain conditions like working for a set time. They are like a gift promised today that you receive later, which can become valuable if the company's stock price goes up. RSUs matter because they are a way companies reward employees and can be a significant part of compensation.

2022 Omnibus Securities and Incentive Plan financial

"as compensation under Neuraxis, Inc. 2022 Omnibus Securities and Incentive Plan"

vesting financial

"The RSUs vest in three equal annual installments over a three-year period"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

FAQ

What equity award did NRXS grant to CEO Brian Allen Carrico?

Brian Allen Carrico received a grant of 193,329 restricted stock units (RSUs) as compensation under Neuraxis, Inc. 2022 Omnibus Securities and Incentive Plan, as amended, according to this Form 4.

How do the NRXS RSUs granted to Brian Allen Carrico vest?

The 193,329 RSUs granted to Brian Allen Carrico vest in three equal annual installments over a three-year period, meaning one-third of the units become vested each year during that timeframe.

Was the NRXS CEO’s RSU transaction under a Rule 10b5-1 trading plan?

No. The filing’s Rule 10b5-1 checkbox is not marked as affirmative, indicating this RSU compensation grant was not reported as being made pursuant to a Rule 10b5-1 trading plan.

What is the transaction price field for the NRXS RSU grant to the CEO?

The Form 4 reports a transaction price per unit of $6.2800 for the 193,329 RSUs. This figure is disclosed in the transaction data field associated with the equity award.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 08/17/2026 - 06:25 PM Accepted by SEC EDGAR 08/17/2026 - 06:25 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Carrico Brian Allen

(Last)

(First)

(Middle)

11611 N. MERIDIAN ST, SUITE 330

(Street)

CARMEL

INDIANA

46032

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Neuraxis, INC [ NRXS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	Chief Executive Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/13/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
RSU	⁽¹⁾	08/13/2026		A		193,329		⁽¹⁾	⁽¹⁾	Common Stock	193,329	$6.28	193,329	D

Explanation of Responses:

1. These shares of common stock are restricted stock units (RSUs) granted to the reporting person as compensation under Neuraxis, Inc. 2022 Omnibus Securities and Incentive Plan, as amended. The RSUs vest in three equal annual installments over a three-year period.

	/s/ Brian Carrico	08/17/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR